We are looking forward to joining the global Parkinson’s community at the annual conference of The Michael J. Fox Foundation for Parkinson’s Research, and to discussing the progress of 𝗟𝗬𝗦𝟮𝟰𝟭, Lys Therapeutics‘ first-in-class neurovascular immunotherapy developed for Parkinson’s disease and other #synucleinopathies, including multiple system atrophy.

An important opportunity to exchange with leading researchers, biopharma partners and investors as we advance toward the clinic.

📍 New York City
📅 October 14–15, 2026

#MJFF #PDTC #ParkinsonsDisease #MSA #LYS241 #LysTherapeutics #Neuroscience #Neurodegeneration #Biotech